For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).
Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...
Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial. Extended endocrine therapy after 5 years of adjuvant LHRH-agonist in premenopausal patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results